A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes
Key facts
- Who runs it
- Assembly Biosciences
- Where
- Australia and New Zealand15 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 115 people enrolled
- Started
- 30 May 2024
- Ended
- 3 Feb 2026
- Type of study
- Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- ABI-5366
- ABI-5366 Placebo
- Record updated
- 30 March 2026
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (14)Hide the full registry criteria
Other criteria
- Part A: Inclusion Criteria:
- Subject has a body mass index (BMI) between ≥ 18.0 and < 32.0 kg/m2
- In good health (as determined by the Investigator) based on medical history, physical examination, ECG, and clinical laboratory results
- Female subjects must be non-pregnant and have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day -1 or Day 1 (predose)
- Agreement to comply with protocol-specified contraceptive requirements; Part B: Inclusion Criteria:
- Subject has a body mass index (BMI) between ≥ 18.0 and < 32.0 kg/m2
- Other than HSV infection, is in good health (as determined by the Investigator) based on medical history, physical examination, ECG, and clinical laboratory results
- Female subjects must be non-pregnant and have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day 1 (predose)
- Agreement to comply with protocol-specified contraceptive requirements; Part A and B: Exclusion Criteria:
- Current infection of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), acute hepatitis A virus (HAV), or acute hepatitis E virus (HEV)
- History of any illness that, in the opinion of the Investigator, might confound the results of the study, pose an additional risk in administering study drug to the subject, or a condition known to interfere with the absorption/distribution/elimination of drugs
- History of any significant drug-related allergic reactions such as anaphylaxis, Stevens-Johnson syndrome, urticaria, or multiple drug allergies
- History of persistent alcohol abuse or illicit drug abuse within 3 years prior to Screening
- Has participated in a clinical study involving administration of either an investigational or a marketed drug within 30 days or 5 half-lives before Screening, whichever is longer
Where is this trial?
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-5366 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-5366 in Part B in participants seropositive for Herpes Simplex Virus Type 2 (HSV-2) with recurrent genital herpes. Effect of food will also be evaluated in Part A.
The 5 groups in the trial
- Part A: SAD Cohorts 1-5, ABI-5366Treatment being tested
Single dose of ABI-5366 (tablet) in Part A for Cohorts 1-5
Treatment: ABI-5366 and ABI-5366 Placebo
- Part A: SAD Cohorts 1-5, PlaceboPlacebo, for comparison
Single dose of matching placebo (tablet) in Part A for Cohorts 1-5
Treatment: ABI-5366 and ABI-5366 Placebo
- Part A: SAD Fed Cohort 6, ABI-5366Treatment being tested
Single dose of ABI-5366 (tablet) in Part A for Cohort 6, food effect
Treatment: ABI-5366
- Part B: MAD Cohorts 1-4 ABI-5366Treatment being tested
Weekly or monthly dose of ABI-5366 (tablet) in Part B for Cohorts 1-4. May have a loading dose.
Treatment: ABI-5366 and ABI-5366 Placebo
- Part B: MAD Cohorts 1-4 PlaceboPlacebo, for comparison
Weekly or monthly dose of matching placebo (tablet) in Part B for Cohorts 1-4. May have a loading dose.
Treatment: ABI-5366 and ABI-5366 Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-5366 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes
- Record updated
- 30 March 2026